A detailed history of Kimelman & Baird, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Kimelman & Baird, LLC holds 21,347 shares of BMY stock, worth $1.23 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
21,347
Previous 22,432 4.84%
Holding current value
$1.23 Million
Previous $932 Million 18.56%
% of portfolio
0.09%
Previous 0.08%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$39.66 - $51.75 $43,031 - $56,148
-1,085 Reduced 4.84%
21,347 $1.1 Billion
Q2 2024

Aug 19, 2024

BUY
$40.25 - $52.99 $359,915 - $473,836
8,942 Added 66.29%
22,432 $932 Million
Q2 2021

Aug 17, 2021

SELL
$61.91 - $67.42 $1.87 Million - $2.04 Million
-30,217 Reduced 69.14%
13,490 $901,000
Q3 2019

Dec 10, 2019

SELL
$42.77 - $50.71 $6,885 - $8,164
-161 Reduced 0.37%
43,707 $2.22 Million
Q2 2019

Nov 22, 2019

BUY
$44.62 - $49.34 $1.96 Million - $2.16 Million
43,868 New
43,868 $1.99 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Kimelman & Baird, LLC Portfolio

Follow Kimelman & Baird, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kimelman & Baird, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kimelman & Baird, LLC with notifications on news.